Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
20.17
+0.30 (1.51%)
At close: Apr 24, 2025, 4:00 PM
19.88
-0.29 (-1.44%)
Pre-market: Apr 25, 2025, 7:03 AM EDT
Beam Therapeutics Revenue
In the year 2024, Beam Therapeutics had annual revenue of $63.52M, down -83.18%. Beam Therapeutics had revenue of $30.07M in the quarter ending December 31, 2024, a decrease of -90.49%.
Revenue (ttm)
$63.52M
Revenue Growth
-83.18%
P/S Ratio
26.14
Revenue / Employee
$131,507
Employees
483
Market Cap
1.96B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
BEAM News
- 20 days ago - Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress - GlobeNewsWire
- 24 days ago - Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - Invezz
- 4 weeks ago - Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration - GlobeNewsWire
- 4 weeks ago - Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy - Seeking Alpha
- 6 weeks ago - Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity - Benzinga
- 6 weeks ago - Beam Therapeutics Announces Pricing of Underwritten Offering - GlobeNewsWire
- 6 weeks ago - Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation - GlobeNewsWire
- 2 months ago - Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts - GlobeNewsWire